

Treatment of Graves' ophthalmopathy with Simvastatin (GO-S)

NCT03131726

Status	RECRUITING
Phase	Phase 3
Sponsor	Lund University
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (3)

- Age 18-70 years
- Active mild to moderate with at least one sign of mild GO (NO SPECS class 2a and b) with reference to Colour Atlas at EUGOGO website (www.eugogo.eu). Exophthalmos up to 24 mm with a disease duration of <18 months (as recorded by the patient)
- Graves' disease with clinical and laboratory euthyroidism after stopping treatment with anti thyroid drugs (ATD), or 2 months treatment with ATD, or euthyroid 6 months after treatment with radioiodine, or euthyroid after total thyroidectomy. Clinical and laboratory euthyroidism is defined as normal fT4, fT3 and TSH below the upper limit of the local reference interval and no clinical symptoms or signs of hyperthyroidism. L-thyroxine is used to achieve euthyroidism during the study period.

Exclusion (13)

- Pregnancy or breast-feeding
- Previous treatment of Graves' ophthalmopathy
- Severe Graves ophthalmopathy requiring corticosteroid treatment, retrobulbar irradiation, orbital decompression surgery
- Current or previous treatment with simvastatin or other statins (within 3 months)
- Allergy (skin rash or systemic reactions) to statins
- ... and 8 more (see full listing online)

Locations (1 total)

Dpt. of Endocrinology, SUS Malmö, Malmo, Sweden